These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 11816865

  • 21. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study.
    Lerner V, Kaptsan A, Miodownik C, Kotler M.
    Clin Neuropharmacol; 1999; 22(4):241-3. PubMed ID: 10442256
    [Abstract] [Full Text] [Related]

  • 22. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
    Akhondzadeh S, Gerami M, Noroozian M, Karamghadiri N, Ghoreishi A, Abbasi SH, Rezazadeh SA.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec 12; 32(8):1810-5. PubMed ID: 18727948
    [Abstract] [Full Text] [Related]

  • 23. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia.
    Goff DC, Renshaw PF, Sarid-Segal O, Dreyfuss DA, Amico ET, Ciraulo DA.
    Biol Psychiatry; 1993 May 15; 33(10):700-6. PubMed ID: 8102552
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM, Bossie CA, Zhu Y, Mao L, Lasser RA.
    Schizophr Res; 2005 Sep 15; 77(2-3):129-39. PubMed ID: 15913962
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
    Lee BJ, Lee JG, Kim YH.
    J Psychopharmacol; 2007 Jun 15; 21(4):421-7. PubMed ID: 17092979
    [Abstract] [Full Text] [Related]

  • 28. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
    Sejil I, Oumaya A, Bouguerra C, Mehdi F, Bellaaj R, Gallali S.
    Encephale; 2013 May 15; 39 Suppl 1():S36-41. PubMed ID: 23219594
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
    Lohr JB, Caligiuri MP.
    J Clin Psychiatry; 1996 Apr 15; 57(4):167-73. PubMed ID: 8601552
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial.
    Diehl A, Reinhard I, Schmitt A, Mann K, Gattaz WF.
    Eur Psychiatry; 2009 Jan 15; 24(1):33-40. PubMed ID: 18774276
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Vitamin E in the treatment of tardive dyskinesia.
    Akhtar S, Jajor TR, Kumar S.
    J Postgrad Med; 1993 Jan 15; 39(3):124-6. PubMed ID: 7914238
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.
    Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP.
    J Clin Psychiatry; 2004 May 15; 65(5):696-701. PubMed ID: 15163258
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.